Balyasny Asset Management
INSY

Balyasny Asset Management’s Insys Therapeutics, Inc. INSY Stock Holding History

Balyasny Asset Management’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-175,000
Closed -$1.55M – 2473
2017
Q3 		$1.55M Buy
+175,000
New +$1.81M 0.01% 1030

Other funds holding INSY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Balyasny Asset Management's INSY Position: Q4 2017 in Review

Balyasny Asset Management sold out of Insys Therapeutics, Inc. (INSY) in Q4 2017, closing a stake of 175,000 shares — an estimated $1.55M sold.

Balyasny Asset Management first reported a position in INSY in Q3 2017 and held it in 1 quarter. The position peaked at $1.55M in Q3 2017. 112 funds tracked by Wall St. Rank hold INSY as of Q4 2017.

  • Balyasny Asset Management reported no remaining Insys Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Balyasny Asset Management sold 175,000 Insys Therapeutics, Inc. shares in Q4 2017, an estimated $1.55M.
  • Balyasny Asset Management first reported a position in Insys Therapeutics, Inc. in Q3 2017 and held it in 1 quarter.
  • Balyasny Asset Management's Insys Therapeutics, Inc. position peaked at $1.55M in Q3 2017.
  • 112 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2017.

Based on Balyasny Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.